Lanean...
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia
ABL tyrosine kinase inhibitors (TKIs) dramatically improves chronic myeloid leukemia (CML) prognosis and most CML patients are now able to lead lives that are equivalent to those of healthy individuals. However, high cost to CML patients of long-term treatment and adverse effects (AEs) remain proble...
Gorde:
| Argitaratua izan da: | Stem Cell Investig |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4981735/ https://ncbi.nlm.nih.gov/pubmed/27583255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2016.07.08 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|